PPA
TCRR

Parametric Portfolio Associates’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Parametric Portfolio Associates’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$119K Sell
43,123
-321,603
-88% -$1.01M ﹤0.01% 3539
2021
Q4 		$1.7M Buy
364,726
+291,040
+395% +$1.82M ﹤0.01% 2535
2021
Q3 		$627K Buy
73,686
+16,696
+29% +$236K ﹤0.01% 3002
2021
Q2 		$935K Buy
56,990
+790
+1% +$16K ﹤0.01% 2800
2021
Q1 		$1.24M Sell
56,200
-752
-1% -$20.5K ﹤0.01% 3057
2020
Q4 		$1.76M Buy
56,952
+5
+0% +$126 ﹤0.01% 2743
2020
Q3 		$1.16M Buy
56,947
+5,318
+10% +$93.4K ﹤0.01% 2825
2020
Q2 		$793K Buy
51,629
+12,623
+32% +$146K ﹤0.01% 3044
2020
Q1 		$302K Buy
39,006
+6,261
+19% +$76.6K ﹤0.01% 3400
2019
Q4 		$468K Buy
32,745
+25
+0.1% +$386 ﹤0.01% 3391
2019
Q3 		$492K Sell
32,720
-2,324
-7% -$36.2K ﹤0.01% 3355
2019
Q2 		$501K Buy
35,044
+6,672
+24% +$106K ﹤0.01% 3363
2019
Q1 		$495K Buy
+28,372
New +$503K ﹤0.01% 3345

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Parametric Portfolio Associates's TCRR Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its TCR2 Therapeutics Inc. Common Stock (TCRR) stake by 88% in Q1 2022, selling an estimated $1.01M and leaving 43,123 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #3539.

Parametric Portfolio Associates first reported a position in TCRR in Q1 2019 and has held it in 13 quarters since. The position peaked at $1.76M in Q4 2020. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Parametric Portfolio Associates held 43,123 shares of TCR2 Therapeutics Inc. Common Stock worth $119K as of Q1 2022.
  • Parametric Portfolio Associates sold 321,603 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $1.01M.
  • TCR2 Therapeutics Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3539 holding.
  • Parametric Portfolio Associates first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and has held it in 13 quarters since.
  • Parametric Portfolio Associates's TCR2 Therapeutics Inc. Common Stock position peaked at $1.76M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.